BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) is often driven by epidermal growth factor receptor (EGFR) mutations.
• Targeting uncommon EGFR mutations, including exon 20 insertions, remains a clinical challenge.
• Developing inhibitors with central nervous system (CNS) activity is crucial for treating brain metastases.

Purpose of the Study:

• To evaluate BLU-451, a novel tyrosine kinase inhibitor, for its potency and selectivity against various EGFR mutations.
• To assess the antitumor activity and CNS efficacy of BLU-451 in preclinical models.
• To examine the preliminary clinical activity and safety of BLU-451 in patients with NSCLC.

Main Methods:

• In vitro enzyme assays and engineered cell lines to determine EGFR mutation selectivity and anti-proliferative effects.
• Cell-derived and patient-derived xenograft models (including intracranial) to assess in vivo antitumor activity.
• Pharmacokinetic/pharmacodynamic (PK/PD) analyses and early-phase clinical trial data (CONCERTO trial).

Main Results:

• BLU-451 demonstrated potent inhibition against a broad spectrum of EGFR mutations, including exon 20 insertions, while sparing wild-type EGFR.
• Robust antitumor activity was observed in preclinical models, with significant CNS efficacy in intracranial models.
• Early clinical data suggest BLU-451 has antitumor activity, including CNS effects, in patients with EGFR mutations.

Conclusions:

• BLU-451 is a potent and selective inhibitor with promising activity against diverse EGFR mutations in NSCLC.
• The drug exhibits potential for CNS penetration and efficacy, addressing a critical unmet need.
• Further clinical evaluation is warranted to fully establish the safety and efficacy profile of BLU-451.